drug_type
RELEVANT_DRUG
intervention_type
Biologic (antibody therapy)
drug_description
Investigational intravenously infused antibody-based therapy targeting CD19 on B cells, intended to eliminate malignant B cells via immune effector mechanisms; evaluated in a first-in-human Phase 1 trial in relapsed/refractory CD19+ B-cell malignancies.
nci_thesaurus_concept_id
C191850
nci_thesaurus_preferred_term
Anti-CD19-Glucosteroid Receptor Modulator ADC ABBV-31
nci_thesaurus_definition
An antibody drug conjugate (ADC) composed of an afucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against the B-cell-specific membrane protein CD19 conjugated to a glucocorticoid receptor (GR) modulator (GRM), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19-GRM ADC ABBV-319 targets and binds to CD19. thereby inducing antibody-dependent cellular cytotoxicity (ADCC). Additionally, by delivering the GRM payload directly to CD19-expressing tumor cells, ABBV-319 inhibits the activation of GR-dependent expression of proliferative and anti-apoptotic genes. This induces apoptosis and inhibits tumor cell proliferation in CD19-expressing tumor cells. CD19 is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies and drives B-cell proliferation. GRMs show robust anti-tumor activity against B-cell malignancies.
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
CD19-targeted, afucosylated IgG1 antibody-drug conjugate that binds CD19 on B cells to trigger ADCC and, after internalization, delivers a glucocorticoid receptor modulator payload that suppresses GR-dependent pro-survival/proliferative gene programs, leading to apoptosis and inhibition of proliferation in CD19+ malignant B cells.
drug_name
ABBV-319
nct_id_drug_ref
NCT05512390